(Reuters) – Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who say they overpaid for EpiPens due to anticompetitive practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.
The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge’s approval, would not resolve claims against Mylan, which is scheduled to face trial in January.
Paul Geller, a lawyer for the plaintiffs, said they were “pleased that Pfizer resolved its part of this class action lawsuit over the pricing of EpiPens.”
Pfizer did not admit wrongdoing. In a statement, the company said that it “denies any wrongdoing and continues to believe that its actions were appropriate.”
The EpiPen is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.
The litigation followed a public outcry in 2016 after Mylan, which owns the rights to market and distribute the devices, raised the price of a pair of EpiPens to $600, from $100 in 2008, putting it in the center of an ongoing U.S. debate over the high cost of medicines.
The lawsuit accused Mylan, which is now part of Viatris Inc, and Pfizer, which manufactured the EpiPen for Mylan, of engaging in anticompetitive conduct that allowed them maintain a monopoly over the market for the devices and their profitable revenues.
U.S. District Judge Daniel Crabtree last month dismissed much of but not all of the claims against Mylan.
The remaining antitrust claims concern a patent settlement the plaintiffs say delayed the launch of a generic epinephrine auto-injector. Mylan has said it “firmly believes that Mylan’s conduct was lawful and pro-competitive.”
Mylan in 2017 agreed to pay $465 million to resolve U.S. Justice Department claims it overcharged the government for the EpiPen.
(Reporting by Nate Raymond in Boston; Editing by Kim Coghill and Sonya Hepinstall)
